Posted by Michael Wonder on 12 Aug 2021
Jazz Pharmaceuticals announces U.S. FDA approval of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution for idiopathic hypersomnia in adults
12 August 2021 - Xywav is the first and only FDA approved treatment for idiopathic hypersomnia.
Jazz Pharmaceuticals today announced that the U.S. FDA approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults.
The company plans to make Xywav available to patients with idiopathic hypersomnia later this year following Risk Evaluation and Mitigation Strategies implementation.
